ASH 2024 Lymphomas

CE / CME

ASH 2024 Conference to Clinic: Lymphomas

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: January 14, 2025

Expiration: August 03, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following is true of first-line treatment with acalabrutinib (A) + venetoclax (V) ± obinutuzumab (O) vs chemoimmunotherapy (CIT) in the phase III AMPLIFY trial in patients with CLL, as presented at ASH 2024?

2.

Which of the following therapies given in combination with lenalidomide/rituximab demonstrated improved PFS with a manageable safety profile for patients with R/R FL in the phase III inMIND trial and may represent a potential new standard of care?

3.

A 77-year-old man with CLL and a complex karyotype and no BTK C481S mutation has come to discuss treatment options with you following disease progression after 3 lines of therapy including acalabrutinib and most recently venetoclax + obinutuzumab. During your consultation with him and his wife, which of the following would you tell him was recently reported with pirtobrutinib versus investigator’s choice of either idelalisib + rituximab or bendamustine + rituximab in the BRUIN CLL-321 phase III trial that enrolled patients with covalent BTK inhibitor-pretreated CLL?